• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AstraZeneca - Articles and news items

AstraZeneca’s lung cancer drug receives full approval in the EU

Industry news / 27 April 2017 / Niamh Marriott, Junior Editor

The EC has granted full marketing authorisation for AstraZeneca’s Tagrisso for the treatment of mutation-positive non-small cell lung cancer (NSCLC)…

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

New drug reduces daily menopausal hot flushes by 73%

Industry news / 6 April 2017 / Niamh Marriott, Junior Editor

In a trial carried out at Imperial College, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by 73%…

AstraZeneca lung cancer drug receives FDA approval

Industry news / 4 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) to treat non-small cell lung cancer (NSCLC)…

AstraZeneca’s potential drug for neuromyelitis optica spectrum disorder receives EU orphan designation

Industry news / 30 March 2017 / Niamh Marriott, Junior Editor

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

Lynparza Phase III data demonstrates progression-free survival in ovarian cancer

Industry news / 17 March 2017 / Niamh Marriott, Junior Editor

AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95% CI 0.22 to 0.41; P<0.0001; […]

AstraZeneca Phase III breast cancer trial met primary endpoint

Industry news / 23 February 2017 / Niamh Marriott, Digital Editor

AstraZeneca announced positive results from its Phase III trial comparing Lynparza to chemotherapy, to treat HER2-negative metastatic breast cancer…


2017 pipelines: AstraZeneca – another challenging year

Blog, Z Homepage promo / 8 February 2017 / Brian White and Paul Taylor, Healthcare analysts, Cantor Fitzgerald Europe

Healthcare analysts predict another difficult year ahead for the pharmaceutical giant, after 2016 was beset with competitive and pricing pressures…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

AstraZeneca head and neck cancer trials resume as FDA lifts clinical hold

Industry news / 23 November 2016 / Niamh Louise Marriott, Digital Content Producer

The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume shortly….

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

NICE recommends first drug for the Cancer Drugs Fund

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

Osimertinib is the first new cancer drug to be introduced into the NHS under a Cancer Drugs Fund managed access agreement…